Novo Nordisk Tightens Operations as Oral Wegovy Pill Sales Double Expectations

The Danish pharmaceutical giant is navigating a tale of two narratives. While its blockbuster weight-loss drug Wegovy continues to smash commercial and clinical targets, the company has abruptly halted construction of a new production facility in Odense, converting the site into a pure logistics hub. The move will eliminate more than half of the 150 planned jobs, a decision confirmed by site director Jesper Trebbien Andersen to the broadcaster TV2.

The pivot in Odense stands in sharp contrast to the upbeat numbers emanating from Novo Nordisk’s first-quarter results. Group revenue soared 32 percent to 96.8 billion Danish kroner, fueled by the surging demand for GLP-1 therapies. Nowhere is that momentum more evident than in the oral formulation of Wegovy, which generated 2.26 billion kroner (roughly $354 million) in Q1 sales — roughly double what analysts had anticipated. Nearly 80 percent of the pill’s users are new to treatment, indicating the oral format is expanding the obesity market rather than cannibalizing the established injectable franchise.

Clinical data presented at the European Congress on Obesity in Istanbul further strengthened Wegovy’s profile. Results from the STEP-UP trial showed that premenopausal women achieved an average weight loss of nearly 23 percent on the high-dose version. The SELECT study, meanwhile, demonstrated robust cardiovascular protection: perimenopausal patients with existing heart disease saw their risk of heart attack and stroke drop by 42 percent, while postmenopausal women recorded a 13 percent risk reduction. Real-world signals also hint at fewer migraines and depressive episodes among Wegovy users, though these observations require confirmation in randomized trials.

Should investors sell immediately? Or is it worth buying Novo Nordisk?

The strong operational performance has not been lost on shareholders. The stock has climbed roughly 25 percent over the past 30 days, currently trading at 40.23 euros. Yet the longer-term picture remains strained: the shares are still down about 31 percent from a year ago and sit below the 200-day moving average, which currently stands at 42.43 euros. The annual high of around 70 euros remains a distant memory.

Management is taking steps to reward investors while tightening its capital strategy. A share buyback program of up to 15 billion kroner is under way; its first tranche concluded in early May. Shareholders can also look forward to the next dividend payment on August 19. On the guidance front, the company has raised its outlook for 2026, buoyed by expectations that the Wegovy pill will roll out in additional international markets starting in the second half of this year.

Meanwhile, a new competitive challenge is brewing in North America. Health Canada recently approved the first generics of Novo Nordisk’s sister drug Ozempic, and the country mandates a steep price reduction once three copies hit the market. Analysts do not expect Canadian pricing pressure to spill over into the United States in the near term, but the development underscores the long-term need for continued innovation and differentiation.

The factory shake-up in Odense, though jarring, reflects a deliberate recalibration. By converting the site into a warehouse, Novo Nordisk is streamlining its capacity footprint even as it races to meet explosive global demand for its obesity and diabetes portfolio. For investors, the immediate test will be whether the stock can reclaim the 200-day line and sustain its recent momentum through a busy second half of the year.

Ad

Novo Nordisk Stock: New Analysis - 13 May

Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Novo Nordisk analysis...

en | DK0062498333 | NOVO | boerse | 69325793 |